S
Sammita Satyanarayan
Researcher at Stanford University
Publications - 8
Citations - 118
Sammita Satyanarayan is an academic researcher from Stanford University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications receiving 60 citations.
Papers
More filters
Journal ArticleDOI
Immunological Aspects of Approved MS Therapeutics.
Paulus S. Rommer,Ron Milo,May H. Han,Sammita Satyanarayan,Johann Sellner,Larissa Hauer,Zsolt Illes,Clemens Warnke,Sarah Laurent,Martin S. Weber,Yinan Zhang,Olaf Stüve +11 more
TL;DR: The objective of this review is to present the modes of action of these drugs and their effects on the immunopathogenesis of MS and each agent's clinical development and potential side effects are discussed.
Journal ArticleDOI
Differential antibody response to COVID-19 vaccines across immunomodulatory therapies for multiple sclerosis
Sammita Satyanarayan,Neha Safi,Tali Sorets,Susan Filomena,Yinan Zhang,Sylvia Klineova,Michelle Fabian,Sam Horng,Stephanie Tankou,Aaron Miller,Stephen Krieger,Fred D. Lublin,James F. Sumowski,Ilana Katz Sand +13 more
TL;DR: In this paper , the impact of DMTs on antibody response to COVID-19 vaccination among MS patients was investigated, and multivariable logistic regression analyses were used to identify clinical and demographic predictors of antibody response.
Journal ArticleDOI
Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy
Ilana Katz Sand,Sacha Gnjatic,Florian Krammer,Kevin Tuballes,Juan Manuel Carreño,Sammita Satyanarayan,Susan Filomena,Erin Staker,J. Tcheou,Aaron E. Miller,Michelle Fabian,Neha Safi,Jamie Nichols,J. Patel,Stephen Krieger,Stephanie Tankou,Sam Horng,Sylvia Klineova,E. T. Beck,Miriam Merad,Fred D. Lublin +20 more
TL;DR: In this paper , the authors evaluated humoral and cellular immune responses to a third COVID-19 vaccine dose in people on anti-CD20 therapy and sphingosine 1-phosphate receptor (S1PR) modulators, including Omicron specific assays.
Posted ContentDOI
Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy
Ilana Katz Sand,Sacha Gnjatic,Florian Krammer,Kevin Tuballes,Juan Manuel Carreño,Sammita Satyanarayan,Susan Filomena,Erin Staker,J. Tcheou,Aaron Miller,Michelle Fabian,Neha Safi,Jamieson Nichols,J. Patel,Stephen Krieger,Stephanie Tankou,Sam Horng,Sylvia Klineova,E. T. Beck,Miriam Merad,Fred D. Lublin +20 more
TL;DR: People treated with anti-CD20 therapy or S1PR modulators and healthy volunteers had impaired antibody neutralization capacity, particularly to BA.1, even after a third vaccine.
Journal ArticleDOI
The impact of relapse definition and measures of durability on MS clinical trial outcomes
Sammita Satyanarayan,Gary Cutter,Stephen Krieger,Stacey S. Cofield,Jerry S. Wolinsky,Fred D. Lublin +5 more
TL;DR: In this article , the authors examined the impact of relapse definition on endpoints and evaluated the durability of progression measures in Relapsing Remitting Multiple Sclerosis (RRMS) trials.